Valneva SE
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company's portfolio includes three commercialized vaccines, including a single-shot vaccine for chikungunya, and products targeted at travelers. Valneva leverages its expertise to advance a broad pipeline of vaccine candidates through clinical development. Key research and development programs include candidates against Lyme disease, Shigella, and Zika.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Valneva SE.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-07 07:17 |
Regulatory News Service
Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du v…
|
French | 218.7 KB | |
| 2025-08-07 07:17 |
Regulatory News Service
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccin…
|
English | 222.5 KB | |
| 2025-07-11 17:35 |
Regulatory News Service
Valneva annonce la levée de la restriction temporaire de l'Agence européenne de…
|
French | 165.8 KB | |
| 2025-07-11 17:35 |
Regulatory News Service
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction …
|
English | 208.0 KB | |
| 2025-06-25 17:45 |
Post-Annual General Meeting Information
Valneva annonce l’approbation des résolutions présentées à son Assemblée Généra…
|
French | 145.4 KB | |
| 2025-06-25 17:45 |
Post-Annual General Meeting Information
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY…
|
English | 119.4 KB | |
| 2025-06-05 17:45 |
Earnings Release
Valneva annonce des résultats positifs de Phase 2 à six mois sur la persistance…
|
French | 236.5 KB | |
| 2025-06-05 17:45 |
Earnings Release
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Resu…
|
English | 178.3 KB | |
| 2025-06-05 07:30 |
Declaration of Voting Results & Voting Rights Announcements
[Valneva SE] Déclaration d’actions et de droits de vote - mai 2025
|
French | 160.2 KB | |
| 2025-06-05 07:30 |
Declaration of Voting Results & Voting Rights Announcements
[Valneva SE] Declaration of shares and voting rights - May 2025
|
English | 170.0 KB | |
| 2025-06-04 07:00 |
Pre-Annual General Meeting Information
Valneva annonce la mise à disposition des documents préparatoires à son Assembl…
|
French | 115.0 KB | |
| 2025-06-04 07:00 |
Pre-Annual General Meeting Information
Valneva Announces Availability of Documentation for its Combined Shareholder Me…
|
English | 122.8 KB | |
| 2025-05-26 17:30 |
Regulatory News Service
Valneva participera à différentes conférences d’investisseurs aux États-Unis et…
|
French | 150.8 KB | |
| 2025-05-26 17:30 |
Regulatory News Service
Valneva to Participate at U.S. and European Investor Conferences in June
|
English | 120.9 KB | |
| 2025-05-12 07:00 |
Regulatory News Service
Valneva fait un point sur les recommandations d’utilisation d'IXCHIQ® chez les …
|
French | 163.7 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
